Brain scans reveal Cobenfy's inner workings in schizophrenia
NCT ID NCT07423546
First seen Feb 27, 2026 · Last updated Apr 29, 2026 · Updated 8 times
Summary
This study looks at how the drug Cobenfy changes dopamine activity in the brains of people with schizophrenia. Twelve participants will take Cobenfy for 5 weeks and get PET and MRI scans before and after treatment. The goal is to understand how the drug works, not to test if it improves symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA 1 (DISORDER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York State Psychiatric Institute
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.